Schwab Andrew J. sold $65K of SKYE (indirect holdings)
Schwab Andrew J. sold 33,892 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at $1.91 across 2 trades on 2026-09-16.
How this was made
The 30-second read
Why it matters
The disclosed sale is a primary source of information but its modest size limits actionable insight.
Market read
The filing provides a factual update on insider holdings with limited market impact.
What to watch
Potential upcoming clinical trial results or regulatory events not disclosed in the filing.
Background
Form 4 filings disclose insider trades and are required to be filed within two business days of the transaction.
Ticker impact
Director Andrew J. Schwab sold 33,892 shares of Skye Bioscience for $64,734 via a Form 4 filing.
Minimal impact; price likely unchanged.
The transaction is a primary disclosure but the amount ($65K) is small for a public company, limiting trading relevance.
Market effects
None; the sale is company‑specific and does not affect the broader biotech sector.
None; the filing is a routine insider transaction.
None; no broader market effect.
Counterpoint
If the insider is reducing exposure ahead of upcoming negative news, the stock could face downside pressure.
Key entities
- CompanySkye Bioscience, Inc.
Biotech firm listed on Nasdaq under ticker SKYE.
- InsiderAndrew J. Schwab
Director and 10% owner of Skye Bioscience.